Recombinant factor VIIa and other pro-haemostatic therapies in primary postpartum haemorrhage

Blood products are an essential component of the management of postpartum haemorrhage, although there is lack of evidence to guide optimal use. Prospective intervention studies, including randomized trials, are needed to clarify optimal timing and dosage. The new generation of virally inactivated bl...

Ausführliche Beschreibung